Insys Therapeutics (INSY) announced Monday it had filed for bankruptcy and will sell most of its assets, just days after agreeing to pay $225 million to settle charges of bribing doctors to boost prescriptions of its addictive painkiller.

The filing, which was widely signaled, also comes weeks after a federal jury in Boston convicted Insys founder and former billionaire John Kapoor, along with four other former executives, of racketeering charges that contributed to the opioid crisis ravaging the U.S.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Insys and the profiteers are getting what is deserved for their utterly ruthless, calloused and endless greed. But where meanwhile are the companies and policies that provide swift access for anti-dotes and for “kick-off” drugs ?????

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy